Corporate Support
Sitemap

Features

Customer Services

Events

Terms of Use

Singapore
Malaysia

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,146.1
-34.9 (-1.10%)

 

  • STI Straits Times Index
    3,146.1
    -34.9 (-1.10%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,490.4
    -40.8 (-2.66%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    26,872.8
    -436.0 (-1.60%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,031.2
    -8.4 (-0.28%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    23,386.7
    -92.4 (-0.39%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    5,799.5
    -82.7 (-1.41%)
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 888.0M
  • Value: 1,070.3M
  • Rise: 46
  • Fall: 306
  • Unch: 462

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol

  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
AusGroup^0.044-0.004
Rex Intl0.181-0.012
Medtecs Intl0.097-
Golden Agri-Res0.205-0.010
YZJ Shipbldg SGD1.000-0.040
ThaiBev0.820-0.025
Singtel3.120+0.020
Broadway Ind^0.077-0.023
OEL0.026-0.002
Kep Infra Tr0.535-0.010

World Indices

World Indices
Name Last Change
Nasdaq 9,576.6 -174.4
HSI 26,855.7 -453.1
HSCEI 10,584.0 -206.8
Jakarta 5,799.9 -82.3
Nikkei 225 23,386.7 -92.4
SSE Comp 3,031.2 -8.4
Shanghai A 3,176.5 -8.8
Shanghai B 244.5 -0.4
KOSPI 2,079.0 -83.8

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help

  • Factsheet

  • Print

GENSCRIPT BIO GENSCRIPT BIO
Quotes 15 Minutes Delayed. Updated at 24 Feb 2020 15:51
Last (HKD): 17.000 Change: -0.500 High: 17.680 Remarks: -
Change (%): -2.86 Low: 16.880
Open 17.500 Yesterday's Close 17.500
Buy Price 17.000 Sell Price 17.020
Buy Volume ('000) 28 Sell Volume ('000) 134
Cumulative Volume ('000) 4,865.2 Cumulative Value 83,082,104
 
Click to show Stock Prices chart

Key Statistics

EPS (HKD) a 0.08834 Trailing EPS (HKD) e -0.09022 NAV (HKD) b 1.8839
PE a 192.438 Trailing PE f - Price / NAV b 9.0238
Dividend (HKD) d - Cash In Hand (HKD) g 1.1777 Issued & Paid-up Shares c 1,882,340,000
Dividend Yield (%) d - Price / Cash In Hand g 14.435 Treasury Shares h -
Beta - 75 Daysi 0.632 R-Squared - 75 Days(%)i 8.33 Market Cap (M) 31,999.780
Beta - 500 Daysi 1.718 R-Squared - 500 Days (%)i 21.09 Enterprise Value (M) 28,306.225
Piotroski F Score 5 Exchange Code 1548 Par Value ( USD ) 0.00100
52 Weeks Volatility (%) 50.95 6-Month VWAP 17.978 Free Float (%) 53.1
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 06 Feb 2020.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 25 Dec 2015.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference GENSCRIPT BIO HKEx 31,999.780 192.438 - 9.0238 -
Industry Biotechnology HKEx 52,667.739 14.860 16.289 6.9231 2.461
Local Peer AMGEN-T HKEx 589,807.000 8.965 9.598 7.8255 4.417
Local Peer WUXI BIO HKEx 148,258.542 198.495 155.179 15.2614 -
Local Peer SINO BIOPHARM HKEx 138,584.698 12.934 13.423 4.1272 0.664
Local Peer BEIGENE HKEx 99,564.622 - - 9.9341 -
Local Peer 3SBIO HKEx 25,374.300 16.774 20.416 2.5009 -
Local Peer ALPHAMAB-B HKEx 17,720.824 - - -49.7278 -
Local Peer HAOHAI BIOTEC HKEx 11,928.704 24.295 26.925 2.8085 0.872
Local Peer FRONTAGE HKEx 10,385.490 117.876 117.881 5.3752 -
Local Peer VIVA BIOTECH HKEx 7,028.190 65.531 65.530 3.6487 -
Local Peer ASCENTAGE-B HKEx 5,333.930 - - -2.8884 -
Local Peer ASCLETIS-B HKEx 4,281.536 - - 1.1108 -
Local Peer SINOMAB BIO-B HKEx 3,652.651 - - - -
Other Local Peers ESSEX BIO-TECH (HKEx), LEE'S PHARM (HKEx), BBI LIFE SCI (HKEx), UNI-BIO GROUP (HKEx), CT ENTERPRISE (HKEx), BIOSINO BIO-TEC (HKEx), REGENT PACIFIC (HKEx), HAO WEN HLDGS (HKEx)
Global Peer AMGEN INC NASDAQ 131,403.102 15.654 16.756 13.5845 2.530
Global Peer CSL ASX 152,685.905 56.910 52.709 - 0.789
Global Peer GILEAD SCIENCES INC NASDAQ 88,240.200 16.176 16.383 3.8958 3.313
Global Peer VERTEX PHARMACEUTICAL NASDAQ 63,855.362 30.460 54.261 10.4935 -
Global Peer BIOGEN INC NASDAQ 58,609.089 13.228 9.953 4.3924 -
Global Peer REGENERON PHARMACEUTICALS INC NASDAQ 44,354.551 18.145 20.963 3.9996 -
Global Peer ILLUMINA INC NASDAQ 43,503.180 52.667 43.416 9.4305 -
Global Peer AGILENT TECHNOLOGIES INC NYSE 26,437.034 83.661 34.603 5.4532 0.717
Global Peer ALEXION PHARMACEUTICAL INC NASDAQ 22,835.299 294.265 9.498 2.0259 -
Global Peer SEATTLE GENETICS INC NASDAQ 20,154.420 - - 10.7416 -
Other Global Peers GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), INCYTE CORPORATION (NASDAQ), BIOMARIN PHARMACEUTICAL (NASDAQ), ALNYLAM PHARMACEUTICALS INC (NASDAQ), EXACT SCIENCES CORP (NASDAQ), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), 10X GENOMICS INC (NASDAQ), BIONTECH SE SPON ADS EACH REP 1 ORD SHS (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), MODERNA INC (NASDAQ), EXELIXIS INC (NASDAQ), ACCELERON PHARMA (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), BLUEBIRD BIO INC (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), Lonza (SGX), MIRATI THERAPEUTICS INC (NASDAQ), FIBROGEN INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), IMMUNOMEDICS INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), EMERGENT BIOSOLUTIONS INC (NYSE), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), ALKERMES PLC (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), INSMED INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), UNIQURE N.V. (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), KODIAK SCIENCES INC (NASDAQ), ALECTOR INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), EPIZYME INC (NASDAQ), VIELA BIO INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), XENCOR INC (NASDAQ), ARVINAS INC (NASDAQ), REGENXBIO INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), VIR BIOTECHNOLOGY INC (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), CORTEXYME INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), MYRIAD GENETICS INC (NASDAQ), POLYNOVO LIMITED (ASX), NEXTCURE INC (NASDAQ), BLACK DIAMOND THERAPEUTICS INC (NASDAQ), BEAM THERAPEUTICS INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), VERACYTE INC (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), AVITA MEDICAL LTD (ASX), ENANTA PHARMACEUTICALS INC (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), AVITA MEDICAL LTD SPON ADS EACH REP 20 ORD SHS (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), DERMIRA INC (NASDAQ), MYOVANT SCIENCES LTD (NYSE), KARYOPHARM THERAPEUTICS INC (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), MESOBLAST LTD (ASX), IMMUNOGEN INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), CYTOKINETICS INC (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), RADIUS HEALTH INC (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), AVROBIO INC (NASDAQ), KADMON HLDGS INC (NYSE), CARA THERAPEUTICS INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), ARCUS BIOSCIENCES INC (NYSE), MOLECULAR TEMPLATES INC (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), PRECIGEN INC (NASDAQ), FREQUENCY THERAPEUTICS INC (NASDAQ), OMEROS CORP (NASDAQ), RETROPHIN INC (NASDAQ), RAPT THERAPEUTICS INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), ARDELYX INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), COMPUGEN (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), INNATE PHARMA SPON ADS EACH REP 1 ORD SHS (NASDAQ), XBIOTECH INC (NASDAQ), BELLUS HEALTH INC (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), KURA ONCOLOGY INC (NASDAQ), NANTKWEST INC (NASDAQ), MACROGENICS INC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), MERUS B V (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), AGENUS INC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), PROTHENA CORP PLC (NASDAQ), TRANSLATE BIO INC (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), SINOVAC BIOTECH LTD (NASDAQ), CUE BIOPHARMA INC (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), ANAPTYSBIO INC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), NANOVIRICIDES INC (NYSE American), DYNAVAX TECHNOLOGIES CORP (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), PDL BIOPHARMA INC (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), CABALETTA BIO INC (NASDAQ), RECRO PHARMA INC (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), MINERVA NEUROSCIENCES INC (NASDAQ), STEMLINE THERAPEUTICS INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), MANNKIND CORPORATION (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), PERSONALIS INC (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), IVERIC BIO INC (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), PFENEX INC (NYSE American), UNITY BIOTECHNOLOGY INC (NASDAQ), ADURO BIOTECH INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), NEUROBO PHARMACEUTICALS INC (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), TELIX PHARMACEUTIC (ASX), KAMADA (NASDAQ), SERES THERAPEUTICS (NASDAQ), DPHARMA (Bursa), VBI VACCINES INC CDA (NASDAQ), GERON CORP (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), NOVAVAX INC (NASDAQ), XOMA CORP (NASDAQ), LIMINAL BIOSCIENCES INC (NASDAQ), IMV INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), NEXT SCIENCE LTD (ASX), LA JOLLA PHARMACEUTICAL CO (NASDAQ), MEDICINOVA INC (NASDAQ), LINEAGE CELL THERAPEUTICS INC (NYSE American), PIERIS PHARMACEUTICALS INC (NASDAQ), AFFIMED N V (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), ATHERSYS INC (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), CHIASMA INC (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), NEUREN PHARMACEUTICALS LTD (ASX), GLYCOMIMETICS INC (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), CONTRAFECT CORP (NASDAQ), VERASTEM INC (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), BRAINSTROM CELL THERAPEUTICS (NASDAQ), CEL-SCI CORP (NYSE American), SOLID BIOSCIENCES INC (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), CELYAD ADS EACH REPR 1 ORD (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), ARAVIVE INC (NASDAQ), EDAP TMS S.A. SPON ADR EACH REPR 1 ORD SHARE (NASDAQ), AVALON GLOBOCARE CORP (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), INFLARX N V (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), AXCELLA HEALTH INC (NASDAQ), SAVARA INC (NASDAQ), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), OTONOMY INC (NASDAQ), IMMUTEP LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), IMMUTEP LTD (ASX), SURFACE ONCOLOGY INC (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), ENZO BIOCHEM INC (NYSE), CHIMERIX INC (NASDAQ), MONOPAR THERAPEUTICS INC (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), AXOVANT GENE THERAPIES LTD (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), IMUGENE LIMITED (ASX), 22ND CENTURY GROUP INC (NYSE American), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), VERMILLION INC (NASDAQ), SYNLOGIC INC (NASDAQ), PALATIN TECHNOLOGIES INC (NYSE American), VACCINEX INC (NASDAQ), EQUILLIUM INC (NASDAQ), SESEN BIO INC (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), COHBAR INC (NASDAQ), ORGENESIS INC (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), ANPAC BIO MEDICAL SCIENCE CO LTD SPON ADS EACH REPR 1 ORD SHS CLASS A (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), CYNATA THERAPEUTICS LTD (ASX), ONCONOVA THERAPEUTICS INC (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), TREVENA INC (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), SOLIGENIX INC (NASDAQ), SYNTHETIC BIOLOGICS INC (NYSE American), LEAP THERAPEUTICS INC (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), NEWLINK GENETICS CORP (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), ADVAXIS INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), INMUNE BIO INC (NASDAQ), RESTORBIO INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), VAXART INC (NASDAQ), BIOTRON (ASX), FORWARD PHARMA AS SPON ADS EACH REP 14 ORD SHS (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), ZAFGEN INC (NASDAQ), CURIS INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), TOCAGEN INC (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), NEON THERAPEUTICS INC (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), INVEX THERAPEUTICS LTD NPV (ASX), T2 BIOSYSTEMS INC (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), ARMATA PHARMACEUTICALS INC (NYSE American), EVOGENE LTD (NASDAQ), MIRAGEN THERAPEUTICS INC (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), ATYR PHARMA INC (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), HOLISTA COLLTECH LIMITED (ASX), ALIMERA SCIENCES INC (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), MEMPHASYS LTD (ASX), KAZIA THERAPEUTICS LIMITED (ASX), ORAGENICS INC (NYSE American), BIOCARDIA INC (NASDAQ), BIONANO GENOMICS INC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), ANTEOTECH LIMITED (ASX), CCP TECHNOLOGIES LTD (ASX), IBIO INC (NYSE American), OCUGEN INC (NASDAQ), SOPHIRIS BIO INC (NASDAQ), GENETIC TECHNOLOGIES (ASX), AZURRX BIOPHARMA INC (NASDAQ), UNUM THERAPEUTICS INC (NASDAQ), BIONOMICS LTD (ASX), CLEVELAND BIOLABS INC (NASDAQ), ACTINOGEN MEDICAL LTD (ASX), APTEVO THERAPEUTICS INC (NASDAQ), ACTINIUM PHARMACEUTICALS INC (NYSE American), CELLECTAR BIOSCIENCES INC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), BIO-PATH HOLDINGS INC (NASDAQ), INDIA GLOBALIZATION CAPITAL INC (NYSE American), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), RHINOMED LIMITED (ASX), HEAT BIOLOGICS INC (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), CONATUS PHARMACEUTICALS INC (NASDAQ), MIDATECH PHARMA PLC SPON ADS EACH REP 20 ORD SHS(R/S) (NASDAQ), CORREVIO PHARMA CORP (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), PRESCIENT THERAPEUTICS LIMITED (ASX), CONTANGO ASSET MANAGEMENT LIMITED (ASX), PRECIPIO INC (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), Suntar Eco-City^ (SGX), CYCLACEL PHARMA IN (NASDAQ), REXAHN PHARMACEUTICALS INC (NASDAQ), PATRYS LIMITED (ASX), ALTERITY THERAPEUTICS LIMITED (ASX), REGENEUS LTD (ASX), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), SIENNA CANCER DIAGNOSTICS LTD (ASX), NOVABAY PHARMACEUTICALS INC (NYSE American), AIM IMMUNOTECH INC (NYSE American), ADALTA LTD (ASX), SENECA BIOPHARMA INC (NASDAQ), BENITEC BIOPHARMA LTD (ASX), ANATARA LIFESCIENCES LTD (ASX), BENITEC BIOPHARMA LTD SPON ADS EA REPR 200 ORD SHS(POST SPLIT) (NASDAQ), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), CELLECT BIOTECHNOLOGY LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), PLUS THERAPEUTICS INC (NASDAQ), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), LIVING CELL TECHNOLOGIES (ASX), ARCA BIOPHARMA INC (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), SENESTECH INC (NASDAQ), AUSTRALIAN PRIMARY HEMP LTD (ASX), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), PHIO PHARMACEUTICALS CORP (NASDAQ), AURIS MEDICAL HOLDING LTD (NASDAQ), SPHERIX INC (NASDAQ), LEAF RESOURCES LTD (ASX), AMPLIA THERAPEUTICS LTD (ASX), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), AVECHO BIOTECHNOLOGY LTD (ASX), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ), NANOLLOSE LTD (ASX), FACTOR THERAPEUTICS LIMITED (ASX), CRYOSITE (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --0.900
-5.03 %
10 Days --2.060
-10.81 %
20 Days --0.600
-3.41 %
Medium Term Return 3 Months --2.160
-11.27 %
6 Months --0.840
-4.71 %
1 Year -+2.800
+19.72 %
Long Term Return 2 Years --7.950
-31.86 %
3 Years 0.012+13.040
+329.60 %
Annualised Return Annualised --
+62.56 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 13.720 - 24.450 Change From 1 Year Low +3.280 % Change From 1 Year Low (%) +23.91
Change From 1 Year High -7.450 % Change From 1 Year High (%) -30.47
2 Years Range 8.600 - 31.700 Change From 2 Years Low +8.400 % Change From 2 Years Low (%) +97.67
Change From 2 Years High -14.700 % Change From 2 Years High (%) -46.37
5 Years Range 1.070 - 34.000 Change From 5 Years Low +15.930 % Change From 5 Years Low (%) +1488.79
Change From 5 Years High -17.000 % Change From 5 Years High (%) -50.00
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Genscript Biotech Corp. is a holding company, which engages in the manufacture and sale of life sciences research products and services. It operates through the following segments: Bio-science Services and Products; Precision Immune-cell Therapy; and Industrial Synthetic Biology Products. The Bio-science Services and Products segment includes life sciences research services, life sciences research catalogue products, and preclinical drug development services. The Precision Immune-cell Therapy segment discovers and develops therapies for the treatment of liquid tumour through optimised CAR structures and the development of bispecific CAR-T therapies. The Industrial Synthetic Biology Products segment comprises of the construction of non-pathogenic microbial strains and industrial enzyme development and production. The company was founded by Fang Liang Zhang, Lu Quan Wang, and Ye Wang in 2002 and is headquartered in Nanjing, China.

Historical Price Data

Date Open High Low Close Volume VWAP
21 Feb 2020 17.500 17.880 17.460 17.500 3,353,435 17.6110
20 Feb 2020 17.740 17.740 17.440 17.520 3,162,534 17.5929
19 Feb 2020 17.600 17.680 17.500 17.600 4,130,650 17.5902
18 Feb 2020 17.900 17.960 17.540 17.720 2,980,000 17.7339
17 Feb 2020 17.900 18.280 17.780 17.900 5,100,000 18.0186
14 Feb 2020 18.200 18.320 17.660 17.900 5,378,000 17.9221
13 Feb 2020 18.640 18.640 18.040 18.200 3,314,000 18.1964
12 Feb 2020 18.540 18.640 18.120 18.640 5,190,327 18.3823
11 Feb 2020 18.840 18.960 18.280 18.400 3,976,849 18.4804
10 Feb 2020 19.060 19.300 18.520 18.700 3,661,000 18.7677
07 Feb 2020 18.940 19.680 18.780 19.060 8,207,956 19.2203
06 Feb 2020 18.860 19.300 18.820 19.040 5,942,602 19.0694
05 Feb 2020 19.000 19.200 18.600 19.000 7,379,000 18.9420
04 Feb 2020 18.780 19.000 18.300 18.760 8,700,675 18.6913
03 Feb 2020 17.880 18.720 17.400 18.340 9,997,297 18.2156
31 Jan 2020 17.660 18.280 17.600 18.040 7,709,000 18.0023
30 Jan 2020 18.360 18.540 17.260 17.500 7,086,105 17.6259
29 Jan 2020 17.000 18.400 16.960 18.360 6,745,000 17.7755
24 Jan 2020 17.100 17.660 17.100 17.600 2,008,361 17.3682
23 Jan 2020 17.940 17.940 17.240 17.420 4,107,117 17.5160
22 Jan 2020 18.200 18.360 17.840 18.220 1,811,682 18.1419
21 Jan 2020 18.740 18.900 17.800 18.200 6,925,822 18.2204
Summary
Current 2 Weeks
(10 Feb 2020 to 21 Feb 2020)		 19.060 19.300 17.440 17.500 40,246,795 -
Previous 2 Weeks
(23 Jan 2020 to 07 Feb 2020)		 17.940 19.300 17.240 19.060 67,883,113 -
4 Weeks from
(23 Dec 2019 to 22 Jan 2020)		 17.940 19.300 17.440 18.220 96,133,509 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.